Endovascular Engineering has developed the Hēlo™ Thrombectomy System, which is designed to address venous thromboembolism (VTE) and pulmonary embolism (PE) through innovative catheter technology. The system features a unique self-expanding funnel design that ensures a wide distal opening for effective engagement with large bore clots. Its dual-action technology combines high-speed agitation with physician-controlled aspiration, allowing for efficient clot breakdown and removal. The catheter's small profile facilitates navigation through complex vascular anatomies, enabling operators to utilize a smaller catheter while still achieving the performance typically associated with larger bore systems. This design minimizes the hemodynamic impact on patients, making it a significant advancement in endovascular care.

The Hēlo™ system is currently being evaluated in the ENGULF Clinical Trial, a multicenter study aimed at assessing its safety, feasibility, and efficacy for treating pulmonary embolism. The trial is structured in two phases: a completed feasibility phase that demonstrated safety in 25 patients, and an ongoing pivotal phase that seeks to establish the system's efficacy for FDA clearance. Endovascular Engineering's commitment to clinical science is underscored by its pioneering efforts in developing a next-generation thrombectomy catheter, which has already been utilized in various U.S. medical centers and is supported by peer-reviewed clinical evidence.

United States

Endovascular Engineering, Inc. ("E2"), is a mission driven, venture-backed company focusing on the development and deployment of groundbreaking clot removal technologies that target venous thromboembolism.

Endovascular Engineering

Company Details